Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$39.19 USD

39.19
848,684

+0.73 (1.90%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $39.21 +0.02 (0.05%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus

by Zacks Equity Research

IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.

Company News for Nov 7, 2024

by Zacks Equity Research

Companies in The News Are: ODP,IONS,JCI,QLYS

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 18.10% and 3.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

by Zacks Equity Research

Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

Viatris to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

VTRS' Q3 results are likely to gain from new product launches in all major geographies.

Gilead Science to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.

Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca Receives CHMP's Approval for Wainzua in Europe

by Zacks Equity Research

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

by Zacks Equity Research

The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.

Kinjel Shah headshot

AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?

by Kinjel Shah

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering

by Zacks Equity Research

IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

by Zacks Equity Research

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?

by Kinjel Shah

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?

by Zacks Equity Research

Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.

The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi

by Zacks Equity Research

AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.

Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises

by Zacks Equity Research

Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.

Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 52.63% and 52.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.